In addition to forming a commercial relationship with Vitura, we also received a cash dividend of approximately $346,000 in Q3, making this the second dividend received from Vitura. Vitura is the market-leading prescriber, patient, pharmacy, and supplier online platform focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the cannabis ecosystem in the Australian medical cannabis market. The Australian market has seen medical cannabis patient approval through the authorized prescriber pathway increase by over 120% year over year to approximately 300,000 approvals as of the first half of 2023, according to the Australian government's Department of Health. Expanding in this market is a top priority for Cronos and we look forward to providing our partners at Vitura with high-quality cannabis products.